Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06690619 · ClinicalTrials.gov registry record · NA
Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function
A NA study, sponsored by Lindenwood University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT06690619 is a NA study that has completed, run by Lindenwood University. The registered enrollment target is 20 participants.
The verdict
NCT06690619, a NA study, has completed, sponsored by Lindenwood University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Purpose: To determine the effects of low dose and high dose Alpha-GPC on cognitive performance, muscle performance, and serum growth hormone levels. Design: Randomized, three-arm, within-subject crossover Study Participants: 21 apparently healthy men to be recruited at a single investigational center in Northeast Ohio 4 Study Visits Study Visit 1: Participants will be screened for participation (i.e., medical history, routine blood work, background baseline diet) Study Visit 2: Participants will ingest one of three supplements (a low dose α-GPC, a high dose α-GPC, or a placebo). Subjects will complete visual analog scale (VAS) questionnaires (assessing mood, motivation, alertness, and concentration) and a cognitive battery (Stroop, Flanker, and N-Back tests) 60 min post ingestion and approximately 3 hours post-ingestion, undergo upper body and lower body power testing and a lower body bout of moderate-intensity exercise 90 min post-ingestion. Also, subjects will undergo blood draws for levels of growth hormone at baseline (prior to supplementation) and 5, 15, 30, and 60 min post lower body bout of exercise. Vital signs and comprehensive side effect profile/ adverse event monitoring will take place throughout the duration of the study. The study will be conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data. Study Visit 3 and 4 Identical to visit 2 with exception of different supplementation being provided. Supplement administration was randomized using a Latin square approach to reduce variability and enhance statistical power Primary Outcomes: Upper and lower body peak force production, peak power production, and peak velocity Secondary Outcomes: Cognitive performance on the Stroop test, Flanker, and N-Back test, serum growth hormone levels, mood, motivation, alertness, and concentration (as assessed by visual analog scales). Tertiary/Safety Outcomes: Vital signs, side effect profile/AE monitoring
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT 315 mg Alpha-GPC
- DIETARY_SUPPLEMENT 630 mg Alpha-GPC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-01-09 |
| Est. Completion | 2024-06-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06690619
The ClinicalTrials.gov registry entry for NCT06690619 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindenwood University, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06690619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06690619 about?
NCT06690619 is a clinical study titled "Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function". Purpose: To determine the effects of low dose and high dose Alpha-GPC on cognitive performance, muscle performance, and serum growth hormone levels. Design: Randomized, three-arm, within-subject crossover Study Participants: 21 apparently healthy men to be recruited at a single investigational cen...
What is the current status of trial NCT06690619?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2024-01-09. Estimated completion is 2024-06-11.
What interventions are being tested in trial NCT06690619?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), 315 mg Alpha-GPC (DIETARY_SUPPLEMENT), 630 mg Alpha-GPC (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06690619?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.